Pages that link to "Q42540665"

The following pages link to The fen-phen finale: a study of weight loss and valvular heart disease (Q42540665):

Displaying 18 items.

• Risk of valvular heart disease associated with use of fenfluramine (Q21261946) (← links)
• Appetite suppressants and valvular heart disease - a systematic review (Q24802870) (← links)
• Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine (Q28370543) (← links)
• Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters (Q28373521) (← links)
• A risk-benefit assessment of anti-obesity drugs (Q33542534) (← links)
• Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity (Q34143853) (← links)
• Rimonabant--a selective CB1 antagonist (Q36065409) (← links)
• Safety of drug therapies used for weight loss and treatment of obesity (Q36433990) (← links)
• Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. (Q36673903) (← links)
• Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases (Q37161908) (← links)
• Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population (Q38681023) (← links)
• Albert J. Stunkard: His Research on Obesity and Its Psychological Impact (Q38714895) (← links)
• What consumers want to know about commercial weight-loss programs: a pilot investigation (Q47173684) (← links)
• Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions (Q47268558) (← links)
• Effects of prenatal co-administration of phentermine and dexfenfluramine in rats (Q48221947) (← links)
• Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. (Q52917335) (← links)
• Obesity in North America. An overview (Q73741109) (← links)
• Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases? (Q90700647) (← links)